PMS (Post-Market Surveillance) is ein proaktiver, systematischer Prozess zur Erfassung und Analyse von Daten über Leistung und Sicherheit von Medizinprodukten nach der Markteinführung.
Complete Guide to PMS
Post-Market Surveillance (PMS) is a mandatory regulatory requirement under EU MDR Articles 83-86 that requires manufacturers to establish and maintain a systematic, proactive process for collecting, recording, and analyzing data about the quality, performance, and safety of medical devices throughout their lifecycle after market placement.
EU MDR requirements:
Under the EU Medical Device Regulation (EU) 2017/745, every manufacturer must:
- Establish a post-market surveillance system appropriate to the risk class and device type
- Develop and maintain a documented PMS plan
- Generate periodic PMS reports (or Periodic Safety Update Reports for higher-risk devices)
- Actively collect and analyze data from multiple sources
PMS plan requirements:
The PMS plan must include:
1. General information - Device identification, classification, risk class
2. Data collection methods - Sources and procedures for gathering data
3. Data analysis methods - Statistical techniques and trend analysis approaches
4. Objectives - Specific safety and performance metrics to monitor
5. Timelines - Frequency of data collection, analysis, and reporting
6. Responsibilities - Roles and responsibilities for PMS activities
7. Vigilance link - Connection to complaint handling and vigilance reporting
Data sources for PMS:
Manufacturers must collect information from:
- Customer feedback - Complaints, returns, service reports
- Clinical data - Post-market clinical follow-up (PMCF) studies
- Literature - Scientific publications and clinical evidence
- Market data - Sales volumes, installation base, usage patterns
- Competent authority reports - Safety communications, field safety notices
- Similar devices - Incidents and safety data from comparable products
- Social media and forums - User experiences and discussions
PMS report requirements:
The PMS report must summarize:
- Data collected during the reporting period
- Evaluation of data and trend analysis
- Number and types of incidents
- Risk-benefit analysis updates
- Volume of sales and estimated population exposed
- Summary of corrective actions taken
- Conclusions and proposed preventive actions
Reporting frequency by risk class:
- Class I - Part of technical documentation, updated as needed
- Class IIa - PMS report updated when technical documentation updated
- Class IIb - PMS report at least every 2 years
- Class III/Implantable - Periodic Safety Update Report (PSUR) annually
Relationship to other post-market activities:
PMS is closely integrated with:
- Vigilance - Mandatory reporting of serious incidents and field safety corrective actions
- PMCF - Clinical follow-up studies to gather clinical safety and performance data
- Trend reporting - Identification of statistically significant increases in incidents
- Risk management - Ongoing evaluation and update of risk analysis
PMS vs PMCF:
| Aspect | PMS | PMCF |
|--------|-----|------|
| Scope | All quality, safety, performance data | Clinical data specifically |
| Methods | Complaints, literature, market data | Clinical studies, registries, surveys |
| Requirement | All devices | Focus on higher-risk devices |
| Output | PMS report or PSUR | PMCF evaluation report |
Compliance considerations:
- PMS is a proactive requirement, not reactive - manufacturers cannot wait for problems
- Insufficient PMS is a leading cause of notified body audit findings
- PMS must be tailored to device risk and specific safety concerns
- Data must be analyzed, not just collected
- PMS plan must be reviewed and updated regularly
PMS is a cornerstone of the EU MDR's lifecycle approach to medical device safety, ensuring that real-world experience continuously informs the risk-benefit evaluation of marketed devices.
Related Terms
More Clinical & Post-Market
View allJedes unerwünschte Ereignis im Zusammenhang mit der Verwendung eines Medizinprodukts, einschließlich Patientenschäden, Verletzungen, Fehlfunktionen oder Beinahe-Vorfällen, die den Aufsichtsbehörden gemeldet werden müssen.
Eine systematische Bewertung, die die klinischen Vorteile eines Medizinprodukts mit seinen Risiken vergleicht, um die Akzeptanz für den vorgesehenen Verwendungszweck zu bestimmen.
Ein umfassendes Dokument, das gemäß EU-MDR erforderlich ist und klinische Daten bewertet und dokumentiert, um die Sicherheit und Leistung eines Medizinprodukts nachzuweisen.
Eine systematische Studie an menschlichen Probanden zur Bewertung der Sicherheit und Leistung eines Medizinprodukts, die gemäß EU-Vorschriften für bestimmte Produkte vor der CE-Kennzeichnung erforderlich ist.
Need Help with EU Registration?
Pure Global provides regulatory consulting and AI-powered tools to help medical device companies navigate EU market access.

